Xenetic Biosciences, Inc. Announces Abstract Accepted for Poster Presentation at the Society for Immunotherapy of Cancer (SITC) Spring Scientific 2025 Cell Therapy Meeting
-
England's Rashford unfazed by high-altitude Mexico World Cup test
-
Iranians begin to gather for Khamenei funeral ceremonies
-
In Brazil, Bolsonaro family airs feud ahead of elections
-
England v Mexico World Cup kickoff could be moved earlier: source
-
Postecoglou links up with Ronaldo at Al Nassr
-
Frustrated families demand recovery of Venezuela's earthquake dead
-
Sabalenka sets up Wimbledon last-16 clash with Osaka
-
Williams sisters return, Swiatek faces Eala test at Wimbledon
-
Dangerous heatwave hits peak temps along US east coast
-
'Ecstatic' Hamilton rolls back the years with Silverstone pole
-
LeBron's agent makes case for 10 new clubs for 41-year-old star
-
England enter World Cup lion's den as Mexico host them at Azteca fortress
-
Trump heads for Mount Rushmore as US turns 250
-
Hamilton beats Antonelli to British GP sprint pole with supreme lap
-
French Top 14 champions Toulouse fined for salary cap breaches
-
Title rivals Djokovic and Sinner advance at Wimbledon
-
Record-equalling Djokovic powers into Wimbledon last 16
-
Ferrari confirm Hamilton staying next year
-
Ruthless Sinner powers into Wimbledon last 16
-
Global frenzy over Swift, Kelce's glittering 'royal wedding'
-
England's Kane feels 'as good as ever' ahead of Mexico World Cup clash
-
Three acquitted of 2019 murder of N.Irish journalist Lyra McKee
-
French Top 14 champions Toulouse fined for salary breaches
-
Stokes bids farewell to fans after 'mad 15 years'
-
Thousands more head for South Africa's borders
-
One for the history books: what we know about the European heatwave
-
Australia upbeat about 'ultimate professional' Perry's fitness for World Cup final
-
Dutch FA to sue over racist slurs after World Cup exit
-
Ukraine backers to vow major support at NATO summit
-
Mercedes demos set stage for wave of German auto protests
-
Ayuso happy to fly under radar at Tour de France
-
Iran leaders pay last respects to Khamenei as mourners gather
-
Curran ready to fill England gap left by Stokes exit
-
UN issues 'red alert' over 'catastrophe' in Sudan's El-Obeid
-
Djokovic has history on the line at Wimbledon
-
Tour de France to start with team time-trial 'bang'
-
Hamilton sparkles in Silverstone sunshine
-
Dressed for success: Osaka reaches Wimbledon last 16 for first time
-
Swift and Kelce set to tie the knot in glitzy arena extravaganza
-
Bayern sign Germany defender Brown until 2031
-
Police hunt for Ukrainian woman over Monaco bomb attack
-
MEXC's June Highlights: $437 Billion in Trading Volume, Offering Access to 7,000+ US Stocks and ETFs
-
Kenya's abortion taboo is killing thousands of women
-
Stocks mostly rise as beaten-down tech stocks enjoy bounce
-
Madonna returns to form with dancefloor filler "Confessions II"
-
Iranian leaders pay respects to supreme leader as Tehran prepares for funeral
-
Dean says Australia final a 'fresh start' for England
-
Doubles not a 'carnival sideshow' say players amid schedule row
-
Wimbledon giving Serena 'as much time' as possible for doubles
-
Klopp in 'talks' for Germany job after Nagelsmann exit: federation
Xenetic Biosciences, Inc. Announces Abstract Accepted for Poster Presentation at the Society for Immunotherapy of Cancer (SITC) Spring Scientific 2025 Cell Therapy Meeting
FRAMINGHAM, MA / ACCESS Newswire / February 27, 2025 / Xenetic Biosciences, Inc. (NASDAQ:XBIO) ("Xenetic" or the "Company"), a biopharmaceutical company focused on advancing innovative immuno-oncology technologies addressing difficult to treat cancers, today announced that its abstract has been accepted for poster presentation at the Society for Immunotherapy of Cancer (SITC) Spring Scientific 2025 Cell Therapy Meeting being held March 12 - 14, 2025 in San Diego, CA and virtually.
Details for the presentation are as follows:
Abstract Number: 123
Title: DNase I Intervention Enhances CAR-T Cell Therapy in Solid Tumors by Targeting Neutrophil Extracellular Traps in Metastatic Melanoma
Presenter: Alexey Stepanov, PhD, Institute Investigator at The Scripps Research Institute
Date & Time: Wednesday, March 12, 2025 at 5:10 p.m. - 6:45p.m. PT
For more information, please visit the conference website here.
About Xenetic Biosciences
Xenetic Biosciences, Inc. is a biopharmaceutical company focused on advancing innovative immuno-oncology technologies addressing difficult to treat cancers. The Company's DNase platform is designed to improve outcomes of existing treatments, including immunotherapies, by targeting neutrophil extracellular traps (NETs), which are involved in the progression of many human cancers. Xenetic is currently focused on advancing its systemic DNase program into the clinic as an adjunctive therapy for pancreatic carcinoma and locally advanced or metastatic solid tumors.
For more information, please visit the Company's website at www.xeneticbio.com and connect on X, LinkedIn, and Facebook.
Contact:
JTC Team, LLC
Jenene Thomas
(908) 824-0775
[email protected]
SOURCE: Xenetic Biosciences, Inc.
View the original press release on ACCESS Newswire
J.Oliveira--AMWN
